Renal Resistance Could Improve Organ Evaluation
FORT LAUDERDALE, Fla.—Renal resistance after three hours of machine perfusion may be a more sensitive marker than renal histology for predicting allograft survival, researchers reported.
Print Issue: March 01, 2010
Preoperative Embolization May Offer Benefits
Angiographic kidney embolization before allograft nephrectomy reduced blood loss, cut operating time.
Post-Transplant Fungal Infections Remain Problematic
Fungal infections, especially invasive candidiasis and invasive aspergillosis, remain problematic among solid organ transplant recipients (SOT), but overall mortality appears to have improved, new findings confirm.
Only Prostate Cancer Clinical Stage Predicts Positive Surgical Margins
Clinical stage is the only preoperative variable independently associated with positive surgical margins (PSMs) following robot-assisted laparoscopic radical prostatectomy (RARP) for prostate cancer, according to researchers.
New Urocit K Formulation Introduced
Mission Pharmacal Company has introduced the Urocit-K 15 mEq (potassium citrate) extended-release tablet.
Research on a New Drug For Nocturia Advances
Vantia Therapeutics, a British pharmaceutical company, has begun a Phase 2b trial of its lead development compound VA106483 for nocturia, according to a company statement.
Drug for Type 2 Diabetes Is Introduced in the U.S.
Victoza (liraglutide [rDNA origin] injection) is now available in the United States, according to the product’s maker, Novo Nordisk.
Safety Plan Announced for Agents Used to Treat Chemo-Related Anemia
The FDA has approved a risk management program to inform health care providers and their patients about the risks of erythropoiesis-stimulating agents (ESAs), which include epoetin alfa and darbepoetin alfa.
Pneumococcal Vaccine with Broader Protection Cleared
The FDA has approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and children aged six weeks through five years.
Olmesartan Cleared for Treating Hypertension in Children
The FDA approved the use of Benicar (olmesartan medoxomil) for the treatment of hypertension in individuals aged 6 to 16 years. The drug original was cleared in 2002 for the treatment of adult hypertension.
- Loading...
Loading...
Loading... 
Loading...